Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Klinische Wirksamkeit (39 Abbildungen)
Übersicht


Zum ersten Bild Abb. 22: Telmisartan - Amlodipin Abb. 23: Telmisartan - Amlodipin Abb. 24: Blutdrucksenkung - Nephropathie Aktuelles Bild - Abb. 25: Niereninsuffizienz - Wirksamkeit Abb. 26: Telmisartan - Eigenschaften Abb. 27: Morgendliche Blutdrucksenkung Abb. 28: Klinische Wirksamkeit - MicardisPlus Zum letzten Bild
Abbildung 25: Niereninsuffizienz - Wirksamkeit
148 haemodialysis patients with chronic renal failure and arterial hypertension were given telmisartan 80 mg or losartan 100 mg daily at 08:00 for 8 weeks.1 Telmisartan provided a better and faster antihypertensive effect than losartan. At 4 weeks, the reduction in SBP/DBP was significantly greater with telmisartan than with losartan (-11.1/-6.2 mmHg versus -4.6/+0.3 mmHg, P<0.05). The superiority of telmisartan increased by Week 8 (-30.6/-10.9 versus -12.3/-4.9 mmHg, P<0.05). 1. Cice G, et al. Unexpected heart rate reduction and antihypertensive efficacy of telmisartan in haemodialysis patients. Presented at the XLI Congress of the European Renal Association, Lisbon, Portugal. May 15–18, 2004.
 
Niereninsuffizienz - Wirksamkeit
Vorheriges Bild Nächstes Bild   


Abbildung 25: Niereninsuffizienz - Wirksamkeit
148 haemodialysis patients with chronic renal failure and arterial hypertension were given telmisartan 80 mg or losartan 100 mg daily at 08:00 for 8 weeks.1 Telmisartan provided a better and faster antihypertensive effect than losartan. At 4 weeks, the reduction in SBP/DBP was significantly greater with telmisartan than with losartan (-11.1/-6.2 mmHg versus -4.6/+0.3 mmHg, P<0.05). The superiority of telmisartan increased by Week 8 (-30.6/-10.9 versus -12.3/-4.9 mmHg, P<0.05). 1. Cice G, et al. Unexpected heart rate reduction and antihypertensive efficacy of telmisartan in haemodialysis patients. Presented at the XLI Congress of the European Renal Association, Lisbon, Portugal. May 15–18, 2004.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung